Merck (NYSE:MRK) announced a major reorganization of its Human Health business into two global units focused on Oncology and ...

The patent cliff for Keytruda is fast approaching in the U.S. Now, as Merck & Co. increasingly looks to life after its oncology megablockbuster, the company is honing its focus on new and upcoming ...

Merck & Co. Inc. MRK shares are up during Monday’s premarket session as the company is evolving its Human Health organization to enhance commercial execution across various therapeutic areas. This ...

The winners will not be those who merely predict cliffs, but those who re-architect early enough. Merck’s oncology spin-out underscores a defining reality of modern pharma: molecules may create value, ...

Merck evolves human health operating structure to support portfolio execution: Rahway, New Jersey Tuesday, February 24, 2026, 13:00 Hrs [IST] Merck, known as MSD outside of the Un ...

Merck MRK announced better-than-expected fourth-quarter 2025 results earlier this month. The company beat estimates for both earnings and sales. Importantly, on the fourth-quarter conference call, ...

Chairman and CEO Robert Davis emphasized the company's portfolio transformation, highlighting, "In 2025, our business benefited from successful new product launches, the advancement of important ...

Merck said on Monday it would split its business into two, creating ⁠a division for its cancer franchise while grouping its ​non-oncology treatments separately.

Merck & Co. MRK and Bristol Myers Squibb BMY are major global drugmakers with expansive, diversified portfolios. Merck stands ...

A giant in the healthcare space, Merck (NYSE:MRK) shares are up 13.5% year-to-date and trading near $119.47, yet retail sentiment on Reddit has slipped from a bullish 63 over the past quarter to a ...